Analysts upgrade today
Piper Jaffray sees Eidos shares rising following AHA presentation. Piper Jaffray analyst Tyler Van Buren maintained an Overweight rating and $55 price target on Eidos Therapeutics following "positive" data from the ongoing Phase II OLE presented at the American Heart Association, or AHA, which suggests that "AG10 may be providing patients with superior long-term outcomes relative to Vyndaqel/tafamidis." Van Buren believes these results suggest that AG10 could be "the best-in-class TTR stabilizer" and the analyst now has a "higher level of confidence in the probability of success of the ongoing Phase III trial." The fly.com
Massive short volume of 32%.
Company profile
Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.
Piper Jaffray sees Eidos shares rising following AHA presentation. Piper Jaffray analyst Tyler Van Buren maintained an Overweight rating and $55 price target on Eidos Therapeutics following "positive" data from the ongoing Phase II OLE presented at the American Heart Association, or AHA, which suggests that "AG10 may be providing patients with superior long-term outcomes relative to Vyndaqel/tafamidis." Van Buren believes these results suggest that AG10 could be "the best-in-class TTR stabilizer" and the analyst now has a "higher level of confidence in the probability of success of the ongoing Phase III trial." The fly.com
Massive short volume of 32%.
Company profile
Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.